Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016174 | 0.84 | PLK1 (0.34) | KMT2APLK1CSNK2A1PLK3 | |
| SCHEMBL24312044 | 0.81 | RXFP1 (0.33) | KMT2APLK1CSNK2A1PLK3 | |
| SCHEMBL22017129 | 0.69 | MEN1 (0.48) | TSHRMEN1KMT2AHTT | |
| SCHEMBL22016209 | 0.68 | ALDH1A1 (0.35) | MEN1KMT2APLK1CSNK2A1PLK3 | |
| SCHEMBL22593916 | 0.65 | RAB9A (0.34) | MEN1KMT2AHTT | |
| SCHEMBL22016171 | 0.65 | KDM4E (0.38) | TSHRMEN1KMT2AHTTHSD17B10 | |
| SCHEMBL31300305 | 0.64 | KDM4E (0.51) | TSHRMEN1KMT2AHTTHSD17B10 | |
| SCHEMBL10252360 | 0.63 | KDM4E (0.36) | TSHR | |
| SCHEMBL24575215 | 0.63 | KMT2A (0.33) | TSHRKMT2A | |
| SCHEMBL10849217 | 0.62 | CRHR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | TSHR 4616/4885MEN1 2786/4885KMT2A 2755/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | TSHR 4616/4885MEN1 2786/4885KMT2A 2755/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | TSHR 4616/4885MEN1 2786/4885KMT2A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.